We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) to Report Q2 Earnings: What's in the Offing?
Read MoreHide Full Article
McKesson Corporation’s (MCK - Free Report) second-quarter fiscal 2020 results are scheduled to release on Oct 30.
In the last reported quarter, the company delivered a positive earnings surprise of 8.9%. Further, it has an average positive surprise of 6.6% for the trailing four quarters.
Let’s take a look at how things are shaping up prior to this announcement.
The Zacks Consensus Estimate for McKesson’s fiscal second-quarter earnings per share is pegged at $3.60. The same for revenues stands at $54.94 billion, suggesting growth of 3.5% from the year-ago reported figure.
Factors to Consider
McKesson expects its fiscal second-quarter results to reflect segmental strength.
The U.S. Pharmaceutical and Specialty Solutions segment is likely to have acted as a key catalyst. In the last reported quarter, the segment had accounted for 79.3% of total revenues.
Notably, the segment is likely to benefit from branded, generic and over-the-counter pharmaceuticals. Also, the company’s broad spectrum of specialty biopharmaceutical providers and manufacturers are expected to have contributed majorly in the second quarter.
Apart from this, management is optimistic about contributions from the Medical-Surgical Solutions segment, driven by acquisitions and growth in the Primary Care and Extended Care businesses. Notably, the acquisition of Medical Specialties Distributor is expected to have proven accretive in the quarter to be reported.
Reflective of these, McKesson has raised its fiscal 2020 view. The company now expects adjusted earnings per share in the range of $14-$14.60 versus the previous $13.85-$14.45.
However, management expects the European Pharmaceutical Solutions unit’s adjusted operating profit growth to be at the low end of its original assumption, thanks to headwinds in Europe. Earlier, concerns in the U.K. had affected McKesson’s fiscal 2019 performance.
Earnings Whispers
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. That is not the case here as you will see below.
Earnings ESP: McKesson has an Earnings ESP of -1.11%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Edward Lifesciences Corporation (EW - Free Report) has an Earnings ESP of +0.35% and a Zacks Rank #3.
AmerisourceBergen Corporation has an Earnings ESP of +0.55% and a Zacks Rank #3.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +1.50% and a Zacks Rank #3.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
McKesson (MCK) to Report Q2 Earnings: What's in the Offing?
McKesson Corporation’s (MCK - Free Report) second-quarter fiscal 2020 results are scheduled to release on Oct 30.
In the last reported quarter, the company delivered a positive earnings surprise of 8.9%. Further, it has an average positive surprise of 6.6% for the trailing four quarters.
Let’s take a look at how things are shaping up prior to this announcement.
McKesson Corporation Price and EPS Surprise
McKesson Corporation price-eps-surprise | McKesson Corporation Quote
Which Way Are Q2 Estimates Headed?
The Zacks Consensus Estimate for McKesson’s fiscal second-quarter earnings per share is pegged at $3.60. The same for revenues stands at $54.94 billion, suggesting growth of 3.5% from the year-ago reported figure.
Factors to Consider
McKesson expects its fiscal second-quarter results to reflect segmental strength.
The U.S. Pharmaceutical and Specialty Solutions segment is likely to have acted as a key catalyst. In the last reported quarter, the segment had accounted for 79.3% of total revenues.
Notably, the segment is likely to benefit from branded, generic and over-the-counter pharmaceuticals. Also, the company’s broad spectrum of specialty biopharmaceutical providers and manufacturers are expected to have contributed majorly in the second quarter.
Apart from this, management is optimistic about contributions from the Medical-Surgical Solutions segment, driven by acquisitions and growth in the Primary Care and Extended Care businesses. Notably, the acquisition of Medical Specialties Distributor is expected to have proven accretive in the quarter to be reported.
Reflective of these, McKesson has raised its fiscal 2020 view. The company now expects adjusted earnings per share in the range of $14-$14.60 versus the previous $13.85-$14.45.
However, management expects the European Pharmaceutical Solutions unit’s adjusted operating profit growth to be at the low end of its original assumption, thanks to headwinds in Europe. Earlier, concerns in the U.K. had affected McKesson’s fiscal 2019 performance.
Earnings Whispers
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. That is not the case here as you will see below.
Earnings ESP: McKesson has an Earnings ESP of -1.11%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: McKesson carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Edward Lifesciences Corporation (EW - Free Report) has an Earnings ESP of +0.35% and a Zacks Rank #3.
AmerisourceBergen Corporation has an Earnings ESP of +0.55% and a Zacks Rank #3.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +1.50% and a Zacks Rank #3.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>